164 related articles for article (PubMed ID: 9736550)
1. Two 2-hydroxy-3-alkyl-1,4-naphthoquinones with in vitro and in vivo activities against Toxoplasma gondii.
Khan AA; Nasr M; Araujo FG
Antimicrob Agents Chemother; 1998 Sep; 42(9):2284-9. PubMed ID: 9736550
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Romand S; Pudney M; Derouin F
Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
[TBL] [Abstract][Full Text] [Related]
3. Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine.
Ferreira RA; Oliveira AB; Ribeiro MF; Tafuri WL; Vitor RW
Exp Parasitol; 2006 Jun; 113(2):125-9. PubMed ID: 16458300
[TBL] [Abstract][Full Text] [Related]
4. Activity of natural and synthetic naphthoquinones against Toxoplasma gondii, in vitro and in murine models of infection.
Ferreira RA; Oliveira AB; Gualberto SA; Vitor RW
Parasite; 2002 Sep; 9(3):261-9. PubMed ID: 12375370
[TBL] [Abstract][Full Text] [Related]
5. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
Martins-Duarte ÉS; de Souza W; Vommaro RC
Exp Parasitol; 2013 Mar; 133(3):294-9. PubMed ID: 23270807
[TBL] [Abstract][Full Text] [Related]
6. Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.
Khan AA; Lambert LH; Remington JS; Araujo FG
Antimicrob Agents Chemother; 1999 Apr; 43(4):758-62. PubMed ID: 10103177
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
Alves CF; Vitor RW
Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831
[TBL] [Abstract][Full Text] [Related]
8. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo FG; Lin T; Remington JS
J Infect Dis; 1993 Feb; 167(2):494-7. PubMed ID: 8421189
[TBL] [Abstract][Full Text] [Related]
9. Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models.
Barbosa BF; Gomes AO; Ferro EA; Napolitano DR; Mineo JR; Silva NM
Vet Parasitol; 2012 Jun; 187(1-2):44-52. PubMed ID: 22281151
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.
Romand S; Della Bruna C; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 Sep; 40(9):2015-20. PubMed ID: 8878573
[TBL] [Abstract][Full Text] [Related]
11. Licochalcone A: An effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo.
Si H; Xu C; Zhang J; Zhang X; Li B; Zhou X; Zhang J
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):238-245. PubMed ID: 29684680
[TBL] [Abstract][Full Text] [Related]
12. Rifabutin is active in murine models of toxoplasmosis.
Araujo FG; Slifer T; Remington JS
Antimicrob Agents Chemother; 1994 Mar; 38(3):570-5. PubMed ID: 8203856
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil.
Silva LA; Fernandes MD; Machado AS; Reis-Cunha JL; Bartholomeu DC; Almeida Vitor RW
Exp Parasitol; 2019 Jul; 202():7-14. PubMed ID: 31077733
[TBL] [Abstract][Full Text] [Related]
14. In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.
Romand S; Bryskier A; Moutot M; Derouin F
J Antimicrob Chemother; 1995 Jun; 35(6):821-32. PubMed ID: 7559193
[TBL] [Abstract][Full Text] [Related]
15. Further evidence that naphthoquinone inhibits Toxoplasma gondii growth in vitro.
da Silva LL; Portes Jde A; de Araújo MH; Silva JL; Rennó MN; Netto CD; da Silva AJ; Costa PR; De Souza W; Seabra SH; DaMatta RA
Parasitol Int; 2015 Dec; 64(6):622-31. PubMed ID: 26335616
[TBL] [Abstract][Full Text] [Related]
16. Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection.
Wei S; Daniel BJ; Brumlik MJ; Burow ME; Zou W; Khan IA; Wadsworth S; Siekierka J; Curiel TJ
Antimicrob Agents Chemother; 2007 Dec; 51(12):4324-8. PubMed ID: 17923491
[TBL] [Abstract][Full Text] [Related]
17. Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice.
Mahmoud MS
J Egypt Soc Parasitol; 1999; 29(3):791-803. PubMed ID: 12561919
[TBL] [Abstract][Full Text] [Related]
18. Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
Araujo FG; Khan AA; Bryskier A; Remington JS
J Antimicrob Chemother; 1998 Nov; 42(5):665-7. PubMed ID: 9848454
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis.
Sordet F; Aumjaud Y; Fessi H; Derouin F
Parasite; 1998 Sep; 5(3):223-9. PubMed ID: 9772721
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of kojic acid against Toxoplasma gondii in experimental models of acute toxoplasmosis.
Montazeri M; Emami S; Asgarian-Omran H; Azizi S; Sharif M; Sarvi S; Rezaei F; Sadeghi M; Gohardehi S; Daryani A
Exp Parasitol; 2019 May; 200():7-12. PubMed ID: 30904693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]